Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma.

ABSTRACT: Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy has significantly improved management of relapsed or refractory multiple myeloma. However, manufacturing failure due to poor cell growth necessitates revision of treatment strategies that negatively impact patients. To identify risk factors for CAR-T manufacturing failure in patients with myeloma, a nationwide cohort study was performed, analyzing patients who underwent apheresis for idecabtagene vicleucel in Japan. Of 154 patients analyzed, 13 cases (8.4%) experienced manufacturing failure. We compared clinical factors between patients with manufacturing failure (failed group) and those who met specifications (successful group). Patients in the failed group had a higher prevalence of deletion 17p at diagnosis (38.5% vs 14.9%), were mo

SUBMITTER: Jo T 

PROVIDER: S-EPMC12182854 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature